30 September 2024
Kromek Group
plc
("Kromek"
or the "Group")
Update on Full Year
Results
Kromek (AIM: KMK), a leading developer
of radiation and bio-detection technology solutions for the
advanced imaging and CBRN detection segments, gives notice
that, further to the Group's trading update
of 29 May 2024 (the "Trading Update") in which it stated it
expected to release its full year results in September 2024, the
Group now expects to announce its final results for the year ended
30 April 2024 during the second half of October.
The Group is experiencing increasing
commercial and strategic momentum and continues to pursue further
initiatives across the business. As noted in the Trading Update,
Kromek expects to report positive EBITDA for FY 2024, ahead of
market expectations. This reflects an anticipated improvement in
gross margin due to the product mix sold combined with the Group
exerting continued tight cost control whilst driving operational
efficiencies, particularly within its advanced imaging
manufacturing process.
Further details will be provided in
the Group's final results announcement.
For
further information, please contact:
|
Kromek Group
plc
|
|
|
Arnab Basu, CEO
Paul Farquhar,
CFO
|
+44 (0)1740 626 060
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
|
|
|
Geoff Nash/Giles Balleny/Seamus
Fricker - Corporate Finance
Tim Redfern - ECM
|
+44 (0)20
7220 0500
|
|
Michael Johnson/Tamar Cranford-Smith - Sales
|
|
|
Gracechurch Group
(Financial PR)
|
|
|
Harry Chathli/Claire Norbury/Henry Gamble
|
+44 (0)20 4582 3500
|
Kromek Group
plc
Kromek Group plc is a leading developer of radiation
detection and bio-detection technology solutions for the advanced
imaging and CBRN detection segments. Headquartered in County
Durham, UK, Kromek has manufacturing operations in the UK and US,
delivering on the vision of enhancing the quality of life through
innovative detection technology
solutions.
The advanced imaging segment comprises the medical,
security and industrial markets. Kromek provides its OEM customers
with detector components, based on its core cadmium zinc telluride
(CZT) platform, to enable better detection of diseases such as
cancer and Alzheimer's, contamination in industrial manufacture and
explosives in aviation settings.
In CBRN detection, the Group provides nuclear
radiation detection solutions to the global homeland defense and
security market. Kromek's compact, handheld, high-performance
radiation detectors, based on advanced scintillation technology,
are primarily used to protect critical infrastructure and urban
environments from the threat of 'dirty
bombs'.
The Group is also developing bio-security solutions
in the CBRN detection segment. These consist of fully automated and
autonomous systems to detect a wide range of airborne
pathogens.
Kromek is listed on AIM, a market of the London Stock
Exchange, under the trading symbol
'KMK'.
Further information is available at
www.kromek.com.